DNA Sequencing Products & Reviews

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

Positive controls provide quality control measures for the verification and validation for point-of-care diagnostic tests including both next-generation sequencing (NGS) and reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

BetterBuffer is a sequence enhancer and BigDye™ (Versions 1.0 & 3.0) dilution buffer that is compatible with ABI sequencing machines (apart from MegaBACE).

Highly purified, Molecular grade water. Strict in-house Quality Control ensures batch-to-batch performance. 1mL, 10mL, and 100mL bottles are available to suit your requirements.

Plasma-SeqSensei™ (PSS) CRC RUO Kit allows the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from plasma of patients with colorectal cancer (CRC). The kit is based on the next-generation sequencing technology and covers key mutations of the MAPK signaling genes KRAS, NRAS and BRAF and the PIK3CA genes. These genes significantly contribute to the development of colorectal cancer and a…

The Plasma-SeqSensei™ (PSS) Melanoma RUO (research use only) Kit allows the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from plasma of patients with melanoma cancer. The kit is based on the next-generation sequencing technology and covers key mutations of the BRAF and NRAS oncogenes. These genes have been shown to enhance tumour growth, promote disease progression and can be consid…

The Plasma-SeqSensei™ (PSS) NSCLC RUO (research use only) Kit detects mutations in circulating tumour DNA (ctDNA) from plasma in patients with non-small cell lung cancer. The kit uses next generation sequencing for the detection and identification of mutations in BRAF, EGFR, KRAS, and PIK3CA genes in human cfDNA isolated from blood plasma which play a significant role in the development of NSCLC and are relevant biomarkers…